title: Targeting BRAK, MEK, mTOR, and now AKT in histiocytosis: The ongoing revolution of therapies in orphan diseases.
authors.affiliation: Service de Médecine Interne 2, Centre National de Référence Maladies Auto-Immunes et Systémiques Rares Lupus et Syndrome des Anticorps Antiphospholipides Institut E3M, Hôpital Pitié-Salpêtrière, Université Paris VI Pierre et Marie, Paris, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Haroche
mesh_terms: D019743:Chemokines, CXC / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016503:Drug Delivery Systems; D005260:Female; D015614:Histiocytosis / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008297:Male; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors* / Q000378:metabolism; D035583:Rare Diseases; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: C118056:CXCL14 protein, human; D019743:Chemokines, CXC; D047428:Protein Kinase Inhibitors; C546842:MTOR protein, human; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; D020930:MAP Kinase Kinase Kinases